Bladder Cancer
An overview of immune checkpoint inhibitor toxicities in bladder cancer.
September 26, 2024
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.
September 25, 2024
Clinical use of nadofaragene firadenovec-vncg.
September 25, 2024
Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.
September 24, 2024
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.
September 23, 2024
HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.
September 23, 2024
Diagnostic accuracy of cytology and urine methylation test in patients with non-muscle invasive bladder cancer: a systematic review and meta-analysis.
September 20, 2024
Investigating the association between blue light cystoscopy utilization and social determinants of health.
September 20, 2024
Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials.
September 20, 2024
Quantitative Nuclear Grading: An Objective, Artificial Intelligence-Facilitated Foundation for Grading Noninvasive Papillary Urothelial Carcinoma.
September 20, 2024
The Feasibility and Efficacy of Multiparametric MRI for Staging Bladder Cancer - Expert Commentary
September 19, 2024
Implementation of Cone Beam Computed Tomography-Guided Online Adaptive Radiotherapy for Challenging Trimodal Therapy in Bladder Preservation: A Report of Two Cases.
September 19, 2024
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
September 18, 2024
Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer.
September 18, 2024
An evaluation of durvalumab across the spectrum of urothelial carcinoma.
September 18, 2024